The importance of co-located, high intensity smoking cessation support within lung cancer screening: Findings from the Process Evaluation of the Yorkshire Enhanced Stop Smoking study

TY - UNPB

T1 - The importance of co-located, high intensity smoking cessation support within lung cancer screening

T2 - Findings from the Process Evaluation of the Yorkshire Enhanced Stop Smoking study

AU - McCutchan, G

AU - Quinn-Scoggins, HD

AU - Tong, H

AU - Smith, P

AU - Quaife, SL

AU - Callister, MEJ

AU - Thorley, R

AU - Baldwin, DR

AU - Beeken, RJ

AU - Copeland, H

AU - Crosbie, PAJ

AU - Lewis, S

AU - Rogerson, S

AU - Wu, Qi

AU - Murray, RL

AU - Brain, K

PY - 2024/7/18

Y1 - 2024/7/18

N2 - Objective Process evaluation of the Yorkshire Enhanced Stop Smoking (YESS) study intervention, to provide evidence regarding optimal integration of smoking cessation support within lung cancer screening (LCS).Design Mixed-methods process evaluation.Setting YESS was a Randomised Controlled Trial testing the effect of personalised smoking cessation support, integrated within LCS. YESS study participants were recruited from the Yorkshire Lung Screening Trial.Participants/data collection Semi-structured interviews with 45 trial participants and eight SCPs 4, 12 and 52-weeks after screening (participants) or training (SCPs). Thematic analysis to assess intervention exposure, context, contamination and theory. Observations of SCP consultations on the screening unit (n=84; 4%) and 4-weeks after screening (n=132; 13%) tested intervention fidelity.Intervention The YESS study tested opt-out, co-located standard best practice (SBP) smoking cessation support (control) versus a theory-informed personalised risk information booklet designed to increase efficacy beliefs in addition to SBP (booklet intervention), delivered by trained smoking cessation practitioners (SCPs).Results Intervention context was paramount: participants in both trial arms described benefits of co-located and ongoing high-intensity smoking cessation support, with immediate provision of pharmacotherapy. Tailored, non-judgemental care was considered key to initiating and sustaining quitting, particularly for participants at various points along their quit or those awaiting their scan result. Fidelity was high (98%) and moderate (75%) for SBP, moderate (77%) for the booklet intervention. Exposure varied by participants’ needs, including their screening results. Potential contamination was observed, with SCPs delivering elements of the booklet intervention training across both trial arms.Conclusions A personalised approach is critical to supporting smoking cessation in LCS. Harnessing the benefits of LCS for supporting cessation at the time of screening requires investment in specialist practitioners to deliver person-centred smoking cessation support.

AB - Objective Process evaluation of the Yorkshire Enhanced Stop Smoking (YESS) study intervention, to provide evidence regarding optimal integration of smoking cessation support within lung cancer screening (LCS).Design Mixed-methods process evaluation.Setting YESS was a Randomised Controlled Trial testing the effect of personalised smoking cessation support, integrated within LCS. YESS study participants were recruited from the Yorkshire Lung Screening Trial.Participants/data collection Semi-structured interviews with 45 trial participants and eight SCPs 4, 12 and 52-weeks after screening (participants) or training (SCPs). Thematic analysis to assess intervention exposure, context, contamination and theory. Observations of SCP consultations on the screening unit (n=84; 4%) and 4-weeks after screening (n=132; 13%) tested intervention fidelity.Intervention The YESS study tested opt-out, co-located standard best practice (SBP) smoking cessation support (control) versus a theory-informed personalised risk information booklet designed to increase efficacy beliefs in addition to SBP (booklet intervention), delivered by trained smoking cessation practitioners (SCPs).Results Intervention context was paramount: participants in both trial arms described benefits of co-located and ongoing high-intensity smoking cessation support, with immediate provision of pharmacotherapy. Tailored, non-judgemental care was considered key to initiating and sustaining quitting, particularly for participants at various points along their quit or those awaiting their scan result. Fidelity was high (98%) and moderate (75%) for SBP, moderate (77%) for the booklet intervention. Exposure varied by participants’ needs, including their screening results. Potential contamination was observed, with SCPs delivering elements of the booklet intervention training across both trial arms.Conclusions A personalised approach is critical to supporting smoking cessation in LCS. Harnessing the benefits of LCS for supporting cessation at the time of screening requires investment in specialist practitioners to deliver person-centred smoking cessation support.

U2 - 10.1101/2024.07.15.24310403

DO - 10.1101/2024.07.15.24310403

M3 - Preprint

T3 - medRxiv

BT - The importance of co-located, high intensity smoking cessation support within lung cancer screening

PB - medRxiv

ER -